QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
NASDAQ:ACRX

AcelRx Pharmaceuticals Stock Forecast, Price & News

$0.51
-0.01 (-1.94%)
(As of 01/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.51
$0.53
50-Day Range
$0.49
$0.79
52-Week Range
$0.46
$2.94
Volume
386,581 shs
Average Volume
1.02 million shs
Market Capitalization
$60.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.71
30 days | 90 days | 365 days | Advanced Chart
Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


AcelRx Pharmaceuticals logo

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.

Headlines

AcelRx Pharmaceuticals's Earnings: A Preview
November 12, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRX
Employees
54
Year Founded
N/A

Sales & Book Value

Annual Sales
$5.42 million
Book Value
($0.56) per share

Profitability

Net Income
$-40.38 million
Net Margins
-1,015.76%
Pretax Margin
-1,015.62%

Debt

Price-To-Earnings

Miscellaneous

Free Float
110,370,000
Market Cap
$60.29 million
Optionable
Optionable

Company Calendar

Last Earnings
11/15/2021
Today
1/20/2022
Next Earnings (Estimated)
3/21/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

899th out of 1,418 stocks

Pharmaceutical Preparations Industry

441st out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

Is AcelRx Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AcelRx Pharmaceuticals stock.
View analyst ratings for AcelRx Pharmaceuticals
or view top-rated stocks.

How has AcelRx Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

AcelRx Pharmaceuticals' stock was trading at $1.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ACRX shares have decreased by 58.6% and is now trading at $0.5053.
View which stocks have been most impacted by COVID-19
.

When is AcelRx Pharmaceuticals' next earnings date?

AcelRx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for AcelRx Pharmaceuticals
.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its earnings results on Monday, November, 15th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.07). The specialty pharmaceutical company had revenue of $1.86 million for the quarter, compared to analysts' expectations of $1.20 million. During the same period in the prior year, the business earned ($0.10) EPS.
View AcelRx Pharmaceuticals' earnings history
.

What price target have analysts set for ACRX?

1 brokers have issued 12 month price targets for AcelRx Pharmaceuticals' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate AcelRx Pharmaceuticals' share price to reach $5.00 in the next year. This suggests a possible upside of 889.5% from the stock's current price.
View analysts' price targets for AcelRx Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the following people:
  • Vincent J. Angotti, Chief Executive Officer & Director
  • Raffi Asadorian, Chief Financial & Accounting Officer
  • Pamela Pierce Palmer, Director & Chief Medical Officer
  • Badri N. Dasu, Chief Engineering Officer
  • Mark A. Evashenk, Vice President-Clinical Operations

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $0.51.

How much money does AcelRx Pharmaceuticals make?

AcelRx Pharmaceuticals has a market capitalization of $60.29 million and generates $5.42 million in revenue each year. The specialty pharmaceutical company earns $-40.38 million in net income (profit) each year or ($0.33) on an earnings per share basis.

How many employees does AcelRx Pharmaceuticals have?

AcelRx Pharmaceuticals employs 54 workers across the globe.

What is AcelRx Pharmaceuticals' official website?

The official website for AcelRx Pharmaceuticals is www.acelrx.com.

Where are AcelRx Pharmaceuticals' headquarters?

AcelRx Pharmaceuticals is headquartered at 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at [email protected], or via fax at 650-216-6500.


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.